Typhoid fever vaccines: A meta-analysis of studies on efficacy and toxicity

British Medical Journal

Volumn 316, Issue 7125, 1998, Pages 110-116

  Engels, Eric A ^a   Falagas, Matthew E ^a   Lau, Joseph ^a   Bennish, Michael L ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TYPHOID VACCINE;

ADOLESCENT; ADULT; AGE; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; EDEMA; FEVER; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; META ANALYSIS; ORAL DRUG ADMINISTRATION; PARENTERAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; TYPHOID FEVER; VACCINATION; VOMITING;

EID: 0032501675     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.316.7125.110     Document Type: Article

References (53)

1. Institute of Medicine. New vaccine development: establishing priorities. Washington, DC: National Academy Press, 1986.
2. Bennish ML. Immunization against Salmonella typhi. Infect Dis Clin Pract 1995;4:114-22.
3. Shadish WR, Haddock CK. In: Cooper H, Hedges LV, eds. The handbook of research synthesis. New York: Russell Sage Foundation, 1994:262.
4. Pearson K. Report on certain enteric fever inoculation statistics. BMJ 1904;ii:1243-6.
5. Yugoslav Typhoid Commission. A controlled field trial of the effectiveness of phenol and alcohol typhoid vaccines: final report. Bull WHO 1962;26:357-69.
6. Ashcroft MT, Ritchie JM, Nicholson CC. Controlled field trial in British Guiana school children of heat-killed phenolized and acetone-killed lyophilized vaccines. Am J Hyg 1964;79:196-206.
7. Yugoslav Typhoid Commission. A controlled field trial of the effectiveness of acetone-dried and inactivated and heat-phenol-inactivated typhoid vaccines in Yugoslavia. Bull WHO 1964;30:623-30.
8. Centers for Disease Control and Prevention. Typhoid immunization. Recommendations of the Advisory Committee on Immunization Practices. MMWR 1994;43:1-8.
9. Typhoid vaccination: weighing the options [editorial]. Lancet 1992;340:341-2.
10. Behrens RH, Roberts JA. Is travel prophylaxis worth while? Economic appraisal of prophylactic measures against malaria, hepatitis A, and typhoid in travellers. BMJ 1994;309:918-22.
11. The Cochrane Library. Cochrane Collaboration; 1997, Issue 3. Oxford: Update Software; 1997. Updated quarterly.
12. Ashcroft MT, Singh B, Nicholson CC, Ritchie JM, Sobryan E, Williams F. A seven-year field trial of two typhoid vaccines in Guyana. Lancet 1967;ii:1056-9.
13. Levine MM, Ferreccio C, Black RE, Germanier R, Chilean Typhoid Committee. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1987;i:1049-52.
14. Levine MM, Ferreccio C, Cryz S, Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet 1990;336:891-4.
15. Polish Typhoid Committee. Controlled field trials and laboratory studies on the effectiveness of typhoid vaccines in Poland, 1961-64. Final report. Bull WHO 1966;34:211-22.
16. Tapa S, Cvjetanovic B. Controlled field trial on the effectiveness of one and two doses of acetone-inactivated and dried vaccine. Bull WHO 1975;52:75-80.
17. Ioannidis JPA, Cappelleri JC, Lau J, Skolnik PR, Melville B, Chalmers TC, et al. Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness: a meta-analysis. Ann Intern Med 1995;122:856-66.
18. Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Tech Assess Health Care 1990;6:5-30.
19. McIntosh MW. The population risk as an explanatory variable in research synthesis of clinical trials. Stat Med 1996;15:1713-28.
20. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987;9:1-30.
21. Cryz SJ, Que JU, Levine MM, Wiedermann G, Kollaritsch H. Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults. Infect Immun 1995;63:1336-9.
22. Cumberland NS, St Clair Roberts J, Arnold WSG, Patel RK, Bowker CH. Typhoid Vi: a less reactogenic vaccine. J Int Med Res 1992;20;247-53.
23. Yugoslav Typhoid Commission. Field and laboratory studies with typhoid vaccines. A preliminary report. Bull WHO 1957;16:897-910.
24. Dimache G, Dimache V, Pavel A, Crottoru M. Intradermal versus subcutaneous typhoid vaccination. Arch Roum Path Exp Microbiol 1981;40:143-7.
25. Dimache G, Croitoru M, Nicolae IN. Subcutaneous versus intradermal typhoid vaccination by "jet injector" apparatus. Arch Roum Path Exp Microbiol 1982;11:259-64.
26. Dimache G. The comparative effectiveness, under epidemic conditions, of the intradermal versus subcutaneous antityphoid vaccination estimated by epidemiological surveillance and laboratory tests. Zentralbl Bakteriol A 1986;262:220-229.
27. Simanjuntak CH, Paleologo FP, Punjabi NH, Darmowigoto R, Soeprawoto, Totosudirjo H, et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 1991;338:1055-9.
28. Wahdan MH, Sérié C, Cerisier Y, Sallam S, Germanier R. A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three year results. J Infect Dis 1982;145:292-5.
29. Black RE, Levine MM, Ferreccio G, Clements ML, Lanata C, Rooney J, et al. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric coated capsules in a controlled field trial. Vaccine 1990;8:81-4.
30. Acharya IL, Lowe CU, Thapa R, Gurubacharya VL, Shrestha MB, Cadoz M, et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi: a preliminary report. N Engl J Med 1987;317:1101-4.
31. Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 1996;14:435-8.
32. Hejfec LB. Results of the study of typhoid vaccines in four controlled field trials in the USSR. Bull WHO 1965;32:1-14.
33. Hejfec LB, Salmin LV, Lejtman MZ, Kuz'minova ML, Vasil'eva AV, Levina LA, et al. A controlled field trial and laboratory study of five typhoid vaccines in the USSR. Bull WHO 1966;34:321-39.
34. Hejfec LB, Levina LA, Kuz'minova ML, Salmin LV, Slavina AM, Vasil'eva AV. Controlled field trials of paratyphoid B vaccine and evaluation of the effectiveness of a single administration of typhoid vaccine. Bull WHO 1968;38:907-15.
35. Hejfec LB, Levina LA, Kuz'minova ML, Slavina AM, Drozd AK, Tonojan IA, et al. A controlled field trial to evaluate the protective capacity of a single dose of acetone-killed agar-grown and heat-killed broth-grown typhoid vaccines. Bull WHO 1969;40:903-7.
36. Levine MM, Tacket CO, Herrington D, Losonsky G, Murphy J, Ferreccio C. The current status of typhoid vaccine development and clinical trials with typhoid vaccines. Southeast Asian J Trop Med Public Health 1988;19:459-69.
37. Levine MM, Taylor DN, Ferreccio C. Typhoid vaccines come of age. Pediatr Infect Dis J 1989;8:374-81.
38. Gilman RH, Hornick RB, Woodward WE, DuPont HL, Snyder MJ, Levine MM, et al. Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a live oral vaccine. J Infect Dis 1977;136:717-23.
39. Murphy JR, Grez L, Schlesinger L, Ferreccio C, Baqar S, Munoz C, et al. Immunogenicity of Salmonella typhi Ty21a vaccine for voting children. Infect Immun 1991;59:4291-3.
40. Rahman S, Barr W, Hilton E. Use of oral typhoid vaccine strain Ty21a in a New York state travel immunization facility. Am J Trop Med Hyg 1993;48:823-6.
41. Cryz SJ, Vanprapar N, Thisyakorn U, Olanratmanee T, Losonsky G, Levine MM, et al. Safety and immunogenicity of Salmonella typhi Ty21a vaccine in young Thai children. Infect Immun 1993;61:1149-51.
42. Levin DM, Wong KH, Reynolds HY, Sutton A, Northrup RS. Vi antigen from Salmonella typhosa and immunity against typhoid fever. II. Safety and antigenicity in humans. Infect Immun 1975;12:1290-4.
43. Klugman KP, Gilbertson IT, Koornhof HJ, Robbins JB, Schneerson R, Schulz D, et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet 1987;ii;1165-9.
44. Tacket CO, Ferreccio C, Robbins JB, Tsai C, Schulz D, Cadoz M, et al. Safety and immunogenicity of two Salmonella typhi Vi capsular polysarcharide vaccines. J Infect Dis 1986;154:342-5.
45. Mirza NB, Wamola IA, Estambale BA, Mbithi K, Poillet M. Typhim Vi vaccine against typhoid fever: a clinical trial in Kenya. East African Med J 1995;72:162-4.
46. Anderson RM, May RM. Immunisation and herd immunity. Lancet 1990;335:641-5.
47. Bodhidatta L, Taylor DN, Thisyakorn U, Echeverria P. Control of typhoid fever in Bangkok, Thailand, by annual immunization of schoolchildren with parenteral typhoid vaccine. Rev Infect Dis 1987;9:841-5.
48. Levine MM, Ferreccio C, Black RE, Tacket CO, Germamier R, Chilean Typhoid Committee. Progress in vaccines against typhoid fever. Rev Infect Dis 1989;11:S552-67.
49. Ferreccio C, Levine MM, Rodriguez H, Contreras R, Chilean Typhoid Committee. Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. J Infec Dis 1989;159:766-9.
50. Joo I. Benefits versus risk factors in cholera and typhoid immunization. Develop Biol Standard 1979;43:47-52.
51. Hirschel H, Wuthrich R, Somaini B, Steffen R. Inefficacy of the commercial live oral Ty 21a vaccine in the prevention of typhoid fever. Eur J Clin Microbiol 1985;4:295-8.
52. Standards of Reporting Trials Group. A proposal for structured reporting of randomized controlled trials. JAMA 1994;272:1926-31.
53. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996;276:637-9.